Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer
Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma
Looking at real world evidence on PSA testing in prostate cancer
Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma
Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas
Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC
Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy
Monitoring ovarian function in oncology studies
Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC
CAR-T, bispecifics or ADCs in late-stage RRMM